- Home
- TCRX vs SRTS Comparison
TCRX vs SRTS Comparison
Compare TCRX & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | SRTS |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 67.5M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TCRX | SRTS |
|---|---|---|
| Price | $1.02 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $8.50 | $8.00 |
| AVG Volume (30 Days) | ★ 717.9K | 64.2K |
| Earning Date | 11-12-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,423,000.00 | ★ $35,609,000.00 |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | $29.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $3.03 |
| 52 Week High | $3.21 | $9.08 |
Technical Indicators
Market Signals| Indicator | TCRX | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 50.78 |
| Support Level | $0.88 | $3.75 |
| Resistance Level | $1.10 | $3.92 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 62.55 | 61.70 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.